“the success of the visible comes from the invisible. Our proficiency in creating the building blocks of medicines has allowed us to go places in the global pharmaceutical marketplace”
	Mr. Satish Khanna Group President API

The global Active Pharmaceutical Ingredients (API) space is driven by the two Asian giants China and India. While India has fewer API players than China, it is more prolific than its counterpart in the API industry largely because of India's Quality and credentials as the best manufacturer of generic formulations worldwide. Lupin is one of the select few API players from India that have made an indelible mark on the global stage. Lupin is also amongst one of the very few pharmaceutical companies globally that are strong players on both fronts of the pharmaceutical business - APIs and Formulations. This makes Lupin a truly formidable, fully-integrated global pharmaceutical company.
 

In FY 2010, the Company's API business generated INR 7,772 million in revenues, representing growth of 9% YOY. This was achieved by focus on improving operational efficiencies with a careful and meticulous product selection strategy.

By maintaining cost leadership and competitiveness in its chosen therapeutic domains, Lupin's API business has been ensuring the profitability and growth of the Company's Formulation business in addition to being a top API supplier globally. Attaining global scale of operations has been the underlying principle governing Lupin's API business model. Being a first mover in specialty products and adding the requisite size and scale into manufacturing new APIs, the Company creates a formidable position for its products in the highly competitive Advanced Markets.
 

Therapeutic Segments Global Ranking Ethambutol 1 Rifampicin 1 Pyrazinamide 2 7 ADCA and Family 1 7 ACCA and Family   1 Lisinopril 1 SABA/SABAM 2 Lovastatin 3 Rifabutin 1

Today, the Company has established global leadership position for its APIs and holds a firm grip in the Cephalosporins, Cardiovascular and Anti-TB space.

Despite the on-going price volatility on PenG, one of the vital inputs for the building blocks of oral Cephalosporins, the Company protected its margins through efficient productivity and prudent procurement planning.

The compounding growth in captive consumption from Lupin's fast expanding Formulations business has added a continual thrust to the volumes produced by the API division. Lupin expects its Formulations business to thrive on the back of efficiencies stemming from its in-house APIs and Intermediates. Over the years and more importantly in the financial year under review, the Company's API output has grown significantly in both volume and value.

Lupin continues to enjoy global market leadership in Rifampicin, Pyrazinamide and Ethambutol, as well as in Cephalosporins such as Cephalexin, Cefaclor and their Intermediates. In FY 2010, the Company continued to record significant growth in the 7-ADCA and 7-ACCA family of products.

The Company is a key supplier of anti-TB formulations to the Global Drug Facility (GDF) and maintained its premier position in the Anti-TB space during the current fiscal.